



## Fortnightly TAG Mail – resources list 27<sup>th</sup> February 2025

---

### NSW TAG ACTIVITIES

---

#### Upcoming NSW TAG Meetings

NSW TAG General Meeting: 12<sup>th</sup> March 2025 4-5.30pm

Contact Sasha Bennett at [sasha.bennett@svha.org.au](mailto:sasha.bennett@svha.org.au) for further information about any email discussions, publications or upcoming meetings.

---

### EDITOR'S PICKS

---

ARD: Efficacy and safety reviews of JKi in immune-mediated inflammatory diseases- [link](#), [link](#)  
BJCP: Adherence and persistence with DOACs by dose regimen: A systematic review - [link](#)  
BJCP: Acute CV effects associated with prescription medications - [link](#)  
BJCP: Navigating challenges and opportunities in orphan medicines - [link](#)  
BJCP: - Understanding factors that influence the drug choice of prescribers - [link](#)  
BMJ: Stroke and MI with contemporary hormonal contraception - [link](#)  
BMJ Open: Comparative effectiveness and safety of nifedipine and Mg SO<sub>4</sub> for preterm birth- [link](#)  
BMJ QS: Problem with reporting standards for adverse event and medical error research - [link](#)  
CADTH: Association Between Opioid Use and the Development of Diverticulitis - [link](#)  
DTB Select: No benefit from bisoprolol for COPD but no increase in serious harms- [link](#)  
EHJ: Translation of genomics into routine cardiological practice - [link](#)  
IMJ: A new era in myeloma: chimeric antigen receptor-T (CAR-T) cells and bispecific antibodies - [link](#)  
IMJ: Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past? - [link](#)  
IJCP: Medication-induced causes of delirium in patients with and without dementia - [link](#)  
IJCP: Genetic polymorphisms and anti-tuberculosis drug-induced liver injury - [link](#)  
JAMA IM: Buprenorphine, Pain, and Opioid Use in Patients on High-Dose Long-Term Opioids- [link](#)  
JAMA IM: Comparative Bleeding Risk in Older Patients With HIV and AF Receiving OACs - [link](#)  
JAMA NO: Harm Reduction Strategies for People Who Use Drugs - [link](#)  
JAMA Psych: Integrated Nicotine Replacement and Behavioral Support for Smoking in OAT- [link](#)  
JAMA Psych: Strengthening Safeguards for Psychiatric Uses of Ketamine - [link](#)  
JACC: Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease- [link](#)  
JACC: Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation - [link](#)  
Lancet: A 5-drug class model using available clinical features to optimise prescribing in T2DM- [link](#)  
Lancet DE: Realigning DM regimens in older adults: simplification and deprescribing strategies - [link](#)  
Lancet ID: - Global guideline for the diagnosis and management of candidiasis - [link](#)  
Lancet ID: Early evidence of RSV vaccination impact on hospitalisation rates of older people - [link](#)  
Lancet ID: DoxyPEP: thinking towards implementation - [link](#)  
Lancet Neur: Enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease - [link](#)  
MJA: Shortages of benzathine benzylpenicillin G in Australia highlight the need for new sovereign manufacturing capability - [link](#)  
MJA: Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia - [link](#)  
MJA: The role of GLP-1 RAs in the management of obesity in the Australian HC system - [link](#)  
Stroke: Thrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window - [link](#)

---

### OTHER NEWS

---

#### NSW Health

- First Japanese encephalitis case this summer [[15 February 2025](#)]
- NSW records first death of person with Japanese encephalitis since 2022 [[25 February 2025](#)]
- Measles alert for Sydney [[21 February 2025](#)] ... for Western Sydney [[26 February 2025](#)]

#### Pharmacy Board of Australia

- Discrimination and racism will not be tolerated - [link](#)

## TGA

- Nitrosamine and Nitroso-structure impurities acceptable intakes update - [link](#)

---

## REPORTS AND PUBLICATIONS – AUSTRALIA

### Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found [here](#)

## CATAG

Collaborating with Consumers: Understanding changing brands of biologics - [link](#)

MAIA Optimising guideline-directed medical therapy for HFREF toolkit - [link](#)

MAIA Perioperative management of SGLT2 inhibitors and GLP-1 receptor agonists toolkit - [link](#)

## Stroke Foundation

- Australian and New Zealand Living Clinical Guidelines for Stroke Management - [link](#)

## TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages

- AusPARs:

-- Gazyva ([obinutuzumab](#)) as pre-treatment to reduce the risk of cytokine release syndrome (CRS) induced by glofitamab

-- [Trugap](#), in combination with fulvestrant, for adult patients with HR positive, HER2 negative locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine-based regimen

-- [Columvi](#) monotherapy with obinutuzumab pretreatment has provisional approval for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Columvi is not indicated for patients with primary central nervous system lymphoma

- Registration of new generic medicines:

-- [LACOSAMIDE INTERPHARMA](#) ; [PANTOPRAZOLE MEDICIANZ](#) ; [ANKSILON](#) (buspirone)

- Registration of extension of indications:

-- [ARCATUS](#) ; [ALHEMO](#) ; [IMFINZI](#) ; [ILARIS](#) ; [BLINCYTO](#) ; [SYFOVRE](#) ; [EMPAVELI](#) ; [KEYTRUDA](#)

---

## REPORTS AND PUBLICATIONS – INTERNATIONAL

### All Wales Medicines Strategy Group

- Emtricitabine/tenofovir alafenamide fumarate ([Descovy](#)®) recommended for restricted use for pre-exposure prophylaxis (PrEP)

### British National Formulary

- BNF/BNFC newsletter: [February 2025](#)

### electronic Medicines Compendium (eMC) (UK)

- [New products](#)

-- Altuvoc (efanesoctocog alfa): a replacement factor VIII therapy, for treatment and prophylaxis of bleeding in patients 2 years and above with severe or moderate haemophilia A ( $\leq 5\%$  endogenous plasma factor VIII activity)

-- Enalto (escitalopram) orodispersible tablets - new formulation: for major depressive episodes, panic disorder with or without agoraphobia, social anxiety disorder, generalised anxiety disorder, and obsessive-compulsive disorder

-- Glycopyrronium Bromide 2mg/5ml Oral Solution - new strength licensed for symptomatic treatment of severe sialorrhoea (chronic pathological drooling) due to chronic neurological disorders of childhood-onset in patients aged 3 years and older

- [Revised SPCs](#)

-- Fasentra (benralizumab) pre-filled pen - as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis

---

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: [nswtag@stvincents.com.au](mailto:nswtag@stvincents.com.au) | [www.nswtag.org.au](http://www.nswtag.org.au)

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Keytruda (pembrolizumab) for first-line treatment of primary advanced or recurrent endometrial carcinoma in adults combined with carboplatin and paclitaxel. Recommended dose is 200 mg every 3 weeks for 6 cycles, then 400 mg every 6 weeks for up to 14 cycles as monotherapy
- Retsevmo (selpercatinib) - extension for use in the first-line treatment of advanced RET fusion positive thyroid cancer

### **Faculty of Sexual and Reproductive Healthcare**

- FSRH statement: Glucagon-like peptide-1 (GLP-1) agonists and oral contraception - [link](#)

### **Food and Drug Administration (FDA) USA**

- New Drug approvals
- rapid-acting insulin biosimilar product ([Merilog](#); insulin-aspart-szjj) for diabetes
- [vimseltinib](#) (Romvimza) for symptomatic tenosynovial giant cell tumor
- Ctexli ([chenodiol](#)), for cerebrotendinous xanthomatosis, a Rare Lipid Storage Disease

### **Medicines and Healthcare products Regulatory Agency (MHRA)**

- Approves medical imaging agent gozetotide (68Ga PSMA-11; Illucix®) for diagnosis of prostate cancer - [link](#)
- Approves efanesoctocog alfa (Altuvoct) to prevent and treat bleeding in children and adults with severe or moderate haemophilia A - [link](#)
- Approves nemolizumab (Nemluvio) for prurigo nodularis and atopic dermatitis (eczema) - [link](#)

### **Monthly Index of Medical Specialities MIMS UK**

- Availability updates for topical psoriasis treatments - [link](#)
- Two new continuous glucose monitoring sensors available for NHS prescribing: FreeStyle Libre 3 Plus sensors and CareSens - [link](#)
- Two new formoterol/beclometasone pMDIs launched - [link](#)
- Oral oestrogen HRT product now available generically - [link](#)
- New MIMS table summarises epilepsy drugs - [link](#)
- New liraglutide biosimilars (Zegluxen and Nevolat) launched - [link](#)

### **NHS England**

- Offering 'new hope' for hundreds of children with severe epilepsy - [link](#)

### **National Audit Office UK**

- Investigation into how government is addressing antimicrobial resistance - [link](#)

### **National Institute for Health and Care Excellence (NICE) UK**

- Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer ([TA1041](#))
- Early and locally advanced breast cancer: diagnosis and management – updated ([NG101](#))
- Ganaxolone for seizures caused by CDKL5 deficiency disorder in people  $\geq 2$  years ([TA1033](#))
- Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer ([TA1042](#))
- Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection ([TA1043](#))
- Exagamglogene autotemcel for severe sickle cell disease in people  $\geq 12$  years ([TA1044](#))

### **National Institute for Health and Care Research (NIHR) Commentaries**

- Can we improve care for women at risk of early birth? - [link](#)
- What impact does hearing loss have on dementia risk? - [link](#)
- Children in deprived areas are most at risk of avoidable poisoning by medicines - [link](#)

### **Public Policy Projects UK**

- How medicines optimisation contributes to population health - [link](#)

## UK Health Security Agency

- Guidelines on post-exposure prophylaxis (PEP) for varicella or shingles (update) - [link](#)
- Hepatitis B vaccine for renal patients: patient group direction template - [update](#)

## World Health Organisation (WHO)

- Alcohol health warning labels: a public health perspective for Europe - [link](#)

---

## MEDICATION SAFETY

---

### Canadian Agency for Drugs and Technologies in Health

- Summary report: Association Between Opioid Use and the Development of Diverticulitis - [link](#)

### electronic Medicines Compendium (eMC) (UK)

#### - [Revised SPCs](#)

- Abraxane - duration of use of effective contraceptive after the last dose of treatment updated for both female patients (from 1 to 6 months) and for male patients with female partners of reproductive potential (from 6 to 3 months)
- Arexvy (RSV vaccine) - Guillain-Barré syndrome reported very rarely following vaccination with Arexvy. In a US post-marketing study, there were an estimated 7 excess cases per million doses administered during the 42 days following vaccination
- Benlysta (belimumab) - serious cutaneous adverse reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) as a warning and undesirable effect with a frequency 'not known'
- Depakote (valproate semisodium) – updated around counselling of female patients on risks of congenital malformations in children exposed to valproate, section 4.5 notes increased risk of neutropenia and myocarditis when used with clozapine, & pleural effusion added as adverse effect
- Epilim (sodium valproate) products - information on risk of congenital malformations & neuro-developmental disorders, and lower weight at birth for gestational age, in children exposed to valproate in utero. Clozapine (CZ) interaction added (increased risk of neutropenia & CZ-induced myocarditis)
- Leustat (cladribine) injection - limited data from cases have shown that cladribine is excreted in breast milk, however the amount has not yet been well established
- Lupkynis (voclosporin) - hypersensitivity (unknown frequency), pneumonia (common) and mouth ulceration (common)
- Opiodur (fentanyl) transdermal – two new contraindications: acute pain (as there is no opportunity for dose titration during short-term use) and post-operative pain (as persistent post-operative opioid use or serious or life-threatening hypoventilation could result)
- Talzenna (talazoparib) capsules - breast-feeding is contra-indicated (previously not recommended) and that it has a minor influence on ability to drive (previously stated it might have a minor influence)
- Toviaz (fesoterodine) prolonged-release tablets - oral hypoaesthesia added as a rare potential ADR
- Vyxeos (cytarabine, daunorubicin) liposomal - updated to note women of childbearing potential should undergo pregnancy testing before initiation of treatment, & both male patients with partners of childbearing potential & female patients should use effective contraception during and for 6 months after treatment
- Veoza (fezolinetant) - “Monitoring of liver function in women with known/suspected hepatic disorder is advised during treatment” deleted; text amended to include monitoring advice for serious cases of liver injury (LFTs prior to & for 1st 3 months, & when symptoms occur)
- Vyvgart (efgartigimiod) concentrate - Nausea added as a common potential ADR
- Xalkori (crizotinib) capsules – for paediatric ALK+ve, unresectable inflammatory myofibroblastic tumours in patients ≥1 year (previously ≥6 years). A new formulation (granules in capsules for opening, 20mg, 50mg and 150mg) has been produced for this use
- Xaluprine (mercaptopurine) - updated to strengthen warnings about immunosuppression, the risks of UV exposure, and interactions with xanthine oxidase inhibitors and ribavirin
- Zyloric (allopurinol) - addition of information on interaction with 6-mercaptopurine and advice that concomitant use should be avoided if possible. Lichenoid drug reaction added as ADR of unknown frequency

---

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: [nswtag@stvincents.com.au](mailto:nswtag@stvincents.com.au) | [www.nswtag.org.au](http://www.nswtag.org.au)

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Risk minimisation materials
- idecabtagene vicleucel ([Abecma](#)) - Materials include an educational guide containing information regarding cytokine release syndrome, neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome and secondary malignancy of T-cell origin. A patient card is also available
- [Propecia Proscar](#) (finasteride) - patient/carer card highlighting the potential for this medicine to cause depression, thoughts of suicide, decreased sex drive and erectile dysfunction, is available
- [deferiprone](#) - reminder card is available for this medicine highlighting the importance of weekly blood monitoring, and for women of childbearing age the need to use effective contraception

#### **EMA**

- Begins review of all available data on suicidal ideation and behaviours with finasteride and dutasteride - [link](#)

#### **Food and Drug Administration (FDA) USA**

- Adds Boxed Warning about anaphylaxis with the multiple sclerosis medicine, glatiramer acetate (Copaxone, Glatopa) - [link](#)

#### **Health Canada – MedEffect Notice**

- Health Product InfoWatch: [February 2025](#)

#### **Medicines and Healthcare products Regulatory Agency (MHRA) UK**

- Drug Safety Update [February 2025](#)

#### **Medsafe (New Zealand Medicines and Medical Devices Safety Authority)**

- Anti-CD20 monoclonal antibodies and the possible risk of pyoderma gangrenosum - [link](#)

---

### **PAPERS OF INTEREST**

#### **Academic Emergency Medicine**

- Comparison of the incidence of recovery agitation with two different doses of ketamine in procedural sedation: A randomized clinical trial - [link](#)

#### **Annals of Internal Medicine**

- De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome: A Systemic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials - [link](#)
- Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults with Type 2 Diabetes: A Target Trial Emulation Study - [link](#)

#### **Annals of the Rheumatic Diseases**

- Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement - [link](#)
- Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement - [link](#)

#### **Australian Prescriber**

- Editorial: Australian Prescriber: celebrating 50 years of growth and change - [link](#)
- Drug safety in pregnancy - [link](#)
- Device-assisted therapies for Parkinson disease - [link](#)
- The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion - [link](#)
- Medicinal mishap: Propranolol overdose following prescription for anxiety - [link](#)
- Editorial: New drug comments: aiming to deliver useful, timely, independent information for health professionals - [link](#)
- New drug - [Etrasimod](#) for moderate to severe ulcerative colitis ; [Mavacamten](#) for symptomatic obstructive hypertrophic cardiomyopathy ; [Teclistamab](#) for relapsed or refractory multiple myeloma

---

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: [nswtag@stvincents.com.au](mailto:nswtag@stvincents.com.au) | [www.nswtag.org.au](http://www.nswtag.org.au)

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- TGA Medicines Safety Update summary: Promethazine hydrochloride ([Phenergan](#)) not to be used in children under 6 ; More prominent safety warnings about the neuropsychiatric effects of [montelukast](#)

### **British Journal of Clinical Pharmacology**

- Adherence and persistence with direct oral anticoagulants by dose regimen: A systematic review - [link](#)
- Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination - [link](#)
- Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population-based cohort of pregnancies - [link](#)
- Navigating challenges and opportunities in orphan medicines: A spotlight commentary on rare diseases - [link](#)
- Acute cardiovascular effects associated with the use of prescription medications: A Danish nationwide screening study - [link](#)
- Prescriptions of CYP3A4- and P-gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention - [link](#)
- Investigation of a broad-spectrum micronutrient formulation as a possible precipitant of pharmacokinetic micronutrient–drug interactions - [link](#)
- Effect of hydration schedules on dose-limiting toxicity in patients with head and neck squamous cell carcinoma treated with cisplatin - [link](#)
- Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B-cell malignancies - [link](#)
- Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial - [link](#)
- Empirical dosage determination of vancomycin for a target area under the concentration-time curve of 400 µg·h/mL in the first 24 h: A prospective multicenter observational study with rich sampling - [link](#)
- Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistant tuberculosis - [link](#)
- The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone - [link](#)
- Understanding factors that influence the drug choice of prescribers: A Q-methodology study - [link](#)

### **British Medical Journal (BMJ)**

- Stroke and myocardial infarction with contemporary hormonal contraception: real-world, nationwide, prospective cohort study - [link](#)
- Practice Pointer: How to recognise and manage measles - [link](#)
- New UK asthma guideline: meeting the challenge to change - [link](#)
- Common interventional procedures for chronic non-cancer spine pain: a systematic review and network meta-analysis of randomised trials - [link](#)
- GLP-1 agonists: 82 deaths linked to adverse reactions according to Yellow Card Scheme data - [link](#)

### **BMJ Open**

- Inhaled methoxyflurane (Pentrox) use in the outpatient and ambulatory setting: a systematic review - [link](#)
- Investigating outcomes in a substance use treatment provider: a cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder - [link](#)
- Effect of statins on neurological functional outcomes in critically ill adult patients with traumatic brain injury: a systematic review and meta-analysis - [link](#)
- Changes in global quality of life after treatment with immune checkpoint inhibitors in patients receiving different treatment regimens for advanced stage lung cancer in the Netherlands: a 2015–2021 cohort study - [link](#)
- Comparative effectiveness and safety of nifedipine and magnesium sulfate as treatment options for preterm birth: a systematic review and meta-analysis - [link](#)

- Medication adherence of patients with peripheral arterial disease to antithrombotic therapy: a systematic review - [link](#)
- Intravenous lidocaine for gut function recovery in colonic surgery: a health economic evaluation of the ALLEGRO randomised clinical trial - [link](#)

### **BMJ Quality & Safety**

- Problem with the existing reporting standards for adverse event and medical error research - [link](#)

### **Circulation**

- Cardiovascular Disease in Anabolic Androgenic Steroid Users - [link](#)
- Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study - [link](#)

### **Cochrane**

- Non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta-analysis - [link](#)
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis - [link](#)
- Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes - [link](#)

### **Diabetes Care**

- Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity - [link](#)

### **Diabetes, Obesity and Metabolism**

- Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis - [link](#)

### **Drug and Therapeutics Bulletin**

- Republished case reports:
  - Airway consequences of alendronic acid aspiration - [link](#)
  - Chronic diarrhoea, weight loss and a positive anti-tissue transglutaminase antibody: a case report of olmesartan-induced enteropathy - [link](#)
  - Drug-induced liver injury secondary to tamoxifen - [link](#)
  - Metformin-associated lactic acidosis: a serious complication of a common drug - [link](#)
  - Topiramate-induced acute eosinophilic pneumonia - [link](#)
- DTB select: No benefit from bisoprolol for COPD - [link](#)

### **European Heart Journal**

- Translation of genomics into routine cardiological practice: insights from a European Society of Cardiology Cardiovascular Round Table - [link](#)

### **European Journal of Hospital Pharmacy**

- Algorithm-managed dosing and pharmacist-managed dosing of erythropoietin stimulating agents in renal anaemia: a systematic review - [link](#)
- Case report: Therapeutic drug monitoring of linezolid in a case of pulmonary nocardiosis: a case report - [link](#)

### **Heart**

- Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial - [link](#)
- Advancing clinical management of left ventricular thrombosis: prevention, detection and treatment modalities in the modern era - [link](#)

- Updated evidence on selection and implementation of an invasive treatment strategy for older patients with non-ST-segment elevation myocardial infarction - [link](#)
- Safety and effectiveness of anticoagulation therapy in older people with atrial fibrillation during exposed and unexposed treatment periods - [link](#)

### **Internal Medicine Journal**

- A new era in myeloma: the advent of chimeric antigen receptor-T (CAR-T) cells and bispecific antibodies - [link](#)
- Use of sodium–glucose cotransporter-2 inhibitors among Aboriginal people with type 2 diabetes in remote Northern Territory: 2012 to 2020 - [link](#)
- Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past? - [link](#)

### **International Journal of Clinical Pharmacy**

- Medication-induced causes of delirium in patients with and without dementia: a systematic review of published neurology guidelines - [link](#)
- Genetic polymorphisms and anti-tuberculosis drug-induced liver injury: an umbrella review of the evidence - [link](#)

### **JAMA**

- CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial - [link](#)
- Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial - [link](#)
- Patient page: Peptic Ulcer Disease - [link](#)

### **JAMA Internal Medicine**

- Buprenorphine, Pain, and Opioid Use in Patients Taking High-Dose Long-Term Opioids: A Randomized Clinical Trial - [link](#)
- Benzocaine-Induced Methemoglobinemia After Nasogastric Tube Insertion: A Teachable moment - [link](#)
- Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral Anticoagulants - [link](#)

### **JAMA Network Open**

- Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial - [link](#)
- Harm Reduction Strategies for People Who Use Drugs - [link](#)

### **JAMA Neurology**

- Verdiperstat in Amyotrophic Lateral Sclerosis: Results from the Randomized HEALEY ALS Platform Trial - [link](#)

### **JAMA Psychiatry**

- Integrated Nicotine Replacement and Behavioral Support to Reduce Smoking in Opioid Agonist Therapy: A Randomized Clinical Trial - [link](#)
- Once-Weekly Semaglutide in Adults with Alcohol Use Disorder - A Randomized Clinical Trial - [link](#)
- Strengthening Safeguards for Psychiatric Uses of Ketamine - [link](#)

### **Journal of Allergy and Clinical Immunology**

- Real-life degradation of epinephrine in adrenaline autoinjectors: A single-center, 12-month prospective observation - [link](#)

### **Journal of the American College of Cardiology**

- Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial - [link](#)
- Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials - [link](#)



- Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS - [link](#)

### **Journal of Clinical Oncology**

- Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma - [link](#)  
- Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma? - [link](#)

### **Lancet**

- Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial - [link](#)  
- Atopic dermatitis - [link](#)  
- A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study - [link](#)

### **Lancet Diabetes & Endocrinology**

- Prediabetes: much more than just a risk factor - [link](#)  
- Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies - [link](#)  
- Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data - [link](#)

### **Lancet Gastroenterology and Hepatology**

- Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective - [link](#)  
- Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis - [link](#)  
- Lancet Series: Management of hepatocellular carcinoma - [link](#)

### **Lancet HIV**

- Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial - [link](#)

### **Lancet Infectious Diseases**

- Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM - [link](#)  
- Early evidence of RSV vaccination impact on hospitalisation rates of older people in Scotland - [link](#)  
- Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim-sulfamethoxazole in Germany: a phase 2/3, prospective, open-label, randomised, controlled, non-inferiority trial - [link](#)  
- DoxyPEP: thinking towards implementation - [link](#)

### **Lancet Neurology**

- Safety and efficacy of nerinetide in patients with acute ischaemic stroke enrolled in the early window: a post-hoc meta-analysis of individual patient data from three randomised trials - [link](#)  
- Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study - [link](#)  
- Clinical insights in enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease - [link](#)

### **Lancet Psychiatry**

- Drug development in psychiatry: 50 years of failure and how to resuscitate it - [link](#)

### **Lancet Regional Health (Europe)**

- Neurodevelopmental outcomes at five years in children born very preterm (24–31 weeks) exposed to opioids with or without midazolam: results from the French nationwide EPIPAGE-2 cohort study - [link](#)
- Biliary tract cancers: addressing healthcare disparities and improving access to innovative treatments in Europe - [link](#)

### **Ophthalmology**

- Risk of Glaucoma in Non-Diabetic Patients using a Glucagon Like Peptide-1 Receptor Agonist - [link](#)

### **Medical Journal of Australia**

- Shortages of benzathine benzylpenicillin G in Australia highlight the need for new sovereign manufacturing capability - [link](#)
- Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus statement - [link](#)
- The role of GLP-1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system - [link](#)

### **Pediatrics**

- Treatment of Obsessive-Compulsive Disorder in Children and Youth: A Meta-Analysis - [link](#)
- Atraumatic Subdural Hematoma in a Patient on Adalimumab - [link](#)

### **Pediatric Dermatology**

- Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial - [link](#)

### **Pharmacotherapy**

- Changes in serum potassium in people with type 2 diabetes taking sodium-glucose co-transporter-2 inhibitors - [link](#)
- GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis - [link](#)
- The potential role of GLP-1 receptor agonists in osteoarthritis - [link](#)
- Comment on “Use of proton pump inhibitors and risk of severe COVID-19: A case–control study in United States Medicare beneficiaries” - [letter](#)

### **Pharmaceutical Journal**

- NHS data show inclisiran prescribed to 7% of expected target population in three years - [link](#)
- The dangers of propranolol for anxiety - [link](#)
- Allergic rhinitis: diagnosis and treatment - [link](#)

### **Stroke**

- Thrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window: A Meta-Analysis of Randomized Clinical Trials - [link](#)

---

## **WEBINARS & PODCASTS**

### **Australian Prescriber Podcasts**

- [Episode 182](#) – A national standard for people living with chronic obstructive pulmonary disease

### **MJA Podcasts**

- [Episode 4](#): Perinatal anxiety and depression

### **Purple Pen Podcast**

- [PPP 171](#) - Proton Pump Inhibitors

---

## UPCOMING EVENTS

---

### AHHA

- Investing in DIAMONDS: transforming a surgical waitlist into a 'preparation list', online 1 April, 2025 12:30-13:30 AEDT - [register](#)
- Mental Health Access & Quality in Emergency Departments, April 8, 2025 09:00 AEST – [register](#)

### Australian Centre for Value-Based Health Care

- 2025 Congress: Partnering to advance VBHC in Australia, 1-2 May 2025, Melbourne - [register](#)